ViewPoint Therapeutics
2014
FOUNDED
PRIVATE
STATUS
11-20
EMPLOYEES
Series B
LATEST DEAL TYPE
$35M
LATEST DEAL AMOUNT
12
INVESTORS
Description
Developer of crystallin stabilizers intended to prevent and treat cataracts and presbyopia. The company's crystallin stabilizers include VP1-001, which is a small molecule that is active in preclinical models of age-related cataracts via a target-based screening and optimization effort, enabling users to get drugs to prevent or reverse protein misfolding, which is implicated in numerous common disorders of aging including cataracts, presbyopia, and neurodegenerative diseases.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
- 290 Utah Avenue
- Suite 300
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore ViewPoint Therapeutics’s full profile, request a free trial.
ViewPoint Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series B) | 05-Mar-2018 | $35M | 0000 | 0000 | Completed | Pre-Clinical Trials |
| 3. Early Stage VC (Series A) | 02-May-2016 | 00.000 | 00.000 | 000.00 | Completed | Pre-Clinical Trials |
| 2. Grant | 01-Apr-2016 | $222K | Completed | Pre-Clinical Trials | ||
| 1. Accelerator/Incubator | 06-Oct-2014 | Completed | Pre-Clinical Trials |
ViewPoint Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
ViewPoint Therapeutics Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lysosomal Therapeutics | Venture Capital-Backed | Cambridge, MA | 00 | 000.00 | 0&0 | |
| 000000000 | Formerly VC-backed | Copenhagen, Denmark | 00 | 00000 | 00000000 | 00000 |
| 00000000 000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000000000 | 00000 |
| 0000 000000000000 | Venture Capital-Backed | Cambridge, United Kingdom | 0000 | 00000000000 | 0000 | |
| 0000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
ViewPoint Therapeutics Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Novo Holdings | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| The Rise Fund | Impact Investing | Minority | 000 0000 | 000000 0 | ||
| Asset Management Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| BVF Partners | Hedge Fund | Minority | 000 0000 | 000000 0 | ||
| Edward Hurwitz | Angel (individual) | Minority | 000 0000 | 000000 0 |
ViewPoint Therapeutics Executive Team (4)
1 Former Executive
You’re viewing 3 of 4 executives. Get the full list »ViewPoint Therapeutics Board Members (6)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Edward Hurwitz | Self | Co-Founder & Chairman | 000 0000 | |
| Emmett Cunningham Ph.D | ViewPoint Therapeutics | Board Member | 000 0000 | |
| Heath Lukatch Ph.D | Novo Holdings | Board Member | 000 0000 | |
| Peter Moldt Ph.D | Novo Holdings | Board Member | 000 0000 |
2 Former Board Members
You’re viewing 4 of 6 board members. Get the full list »